

- use of different types of postmenopausal hormone therapy in a large prospective study. *J Thromb Haemost* 2012. Sep 10. doi: 10.1111/j.1538-7836.2012.04919.x. [Epub ahead of print]
16. Roach RE, Lijfering WM, Helmerhorst FM, Cannegieter SC, Rosendaal FR, van Hylckama Vlieg A. The risk of venous thrombosis in women over 50 years old using oral contraception or postmenopausal hormone therapy. *J Thromb Haemost* 2012;Nov 8. doi: 10.1111/jth.12060. [Epub ahead of print]
 17. Renoux C, Dell’Aniello S, Suissa S. Hormone replacement therapy and the risk of venous thromboembolism: a population-based study. *J Thromb Haemost* 2010; May;8(5):979-986. doi: 10.1111/j.1538-7836.2010.03839.x. Epub 2010 Mar 4.
 18. Laliberté F, Dea K, Duh MS, Kahler KH, Rolli M, Lefebvre P. Does the route of administration for estrogen hormone therapy impact the risk of venous thromboembolism? Estradiol transdermal system versus oral estrogen-only hormone therapy. *Menopause* 2011;18:1052-1059.
 19. Scarabin PY, Oger E, Plu-Bureau G. Estrogen and thromboembolism risk study group. Differential association of oral and transdermal oestrogen-replacement therapy with venous thromboembolism risk. *Lancet* 2003;362:428-432.
 20. Renoux C, Dell’Aniello S, Garbe E, Suissa S. Transdermal and oral hormone replacement therapy and the risk of stroke: a nested case-control study. *BMJ* 2010; 340: c2519. doi: 10.1136/bmj.c2519.
 21. Lee JS, Yaffe K, Lui LY, Cauley J, Taylor B, Browner W, Cummings S. Study of osteoporotic fractures group. Prospective study of endogenous circulating estradiol and risk of stroke in older women. *Arch Neurol* 2010;67:195-201.
 22. Nelken RS, Ozel BZ, Leegant AR, Felix JC, Mishell DR. Randomized trial of estradiol vaginal ring versus oral oxybutynin for the treatment of overactive bladder. *Menopause* 2001;18:962-966.
 23. Eriksen BC. A randomized, open, parallel-group study on the preventive effect of an estradiol releasing vaginal ring (Estring) on recurrent urinary tract infections in postmenopausal women. *Am J Obstet Gynecol* 1999;80:1072-1079.

Conflicto de intereses

El Dr. Kaunitz sirve como consultor para Bayer and Teva (contraception only). Dr. Kaunitz’s Institution recibe fondos para investigación de Bayer (contraception), Endoceutics (vulvovaginal atrophy), Noven (nonhormonal management of vasomotor symptoms) y Teva (contraception).

Estas Perlas Prácticas –*Practice Pearl*–, da información práctica de tópicos controvertidos y de interés clínico. Esta no es una posición oficial de la The North American Menopause Society (NAMS). Los médicos deben tomar siempre en consideración el paciente individualmente junto con los nuevos datos publicados después de la publicación de esta posición el 1 de octubre de 2013.